Post-Market Evidence Generation: Bridging PV and HTA for Long-Term Access
Post-market evidence generation is essential for ensuring the continued safety, effectiveness, and value of health products. By integrating pharmacovigilance (PV) data with health technology assessment (HTA) requirements, stakeholders can support real-world value demonstrations beyond initial approval.